Dr. Wolfram Lux
Teltow
Summary
Dynamic consulting leader with over 20 years of experience in the pharmaceutical and biotech sectors, specializing in the development and scaling of consulting solutions that drive measurable value.
Proven track record as an Oncology Business Unit Head, Market Access General Manager and Senior Director of Access-based Commercial Strategy.
Successfully launched drugs from clinical, commercial, and market access perspectives.
Expertise includes oncology, rare diseases, and cell and gene therapy, complemented by a PhD in Molecular Biology and Bachelor in Business Administration.
Renowned for establishing end-to-end process optimization, corporate transformation and portfolio prioritization frameworks, and cross-functional delivery models that enhance execution speed and promote enterprise-wide best practices.
Overview
24
24
years of professional experience
Work History
Head Drug Development, Value Strategy & Market Acc
Horváth & Partners
04.2024 - Current
- Business Development
- Drug Development, Commercialization & Market Access
- Operating Models / R&D Cost Management
- Drug e-Commerce Europe
- Cell & Gene-therapies / Rare Diseases
- Self-motivated, with a strong sense of personal responsibility, working effectively in fast-paced environments
- Skilled at working independently and collaboratively in a team environment.
- Proven ability to learn quickly and adapt to new situations.
Senior Director, Access Based Commercial Strategy
Simon-Kucher & Partners
03.2019 - 03.2024
- Leading Access Based Commercial Strategy business in Europe with focus on BioTech and Pharma, Oncology, Rare Disease and cell and gene therapies, claims data analyses
Co-Founder and CEO
HTB HealthTechBerlin
01.2018 - 03.2022
- AI-based medical evaluations of patient data records, East-Asia
- Medical Tourism
General Manager, Head of Operations
HGC Healthcare Consulting
09.2015 - 12.2017
- Overseeing all business operations and strategy development for a specialized management consultancy to the Pharma and MedTech industry in DACH region & Europe.
- Health Insurance data risk analyses and reimbursement solutions for MedTech and Pharma
- Data-based Patient Journeys, cost-analyses, customer engagement models and late-stage brand performance optimisation
- Patient risk analyses for the European Union (Horizon 2020)
Business Unit Head, Oncology (interim)
Eisai Pharmaceuticals, Germany
01.2015 - 08.2015
- Interim-Head of Business Unit and Head of Marketing for the launch of Lenvima (Orphan Drug, Thyroid Cancer).
- Leading German launch including, Marketing campaign, Medical Liaison, KOL Management, SFE and wholesaler distribution
- Leading indication extension of Halaven (Breast Cancer) and AMNOG pricing negotiation with German authorities
SENIOR PRINCIPAL
IMS Consulting Group
12.2013 - 01.2015
- Leading Brand and Commercial Strategy Franchise in Germany.
- Brand Planning Excellence implementation
- Prescription data solutions in EU and USA
- Geographic expansion strategy and implementation
Senior Director / PRINCIPAL
Campbell Alliance
09.2011 - 11.2013
- Leading Pricing & Market Access Franchise in Europe. Positioning, Brand and Launch Planning Excellence
Head BU Oncology, EMEA
IMS Health
03.2007 - 08.2011
- Engagement Manager & Principal, German and European Center of Excellence Oncology.
- Oncology Management Consulting
- Global Patient Level Data Analytics, Oncology
- European Database Business, Oncology
- Global database production, Oncology
Medical Liaison Manager, Senior Brand Manager
Schering (Pharmaceuticals), Germany
02.2005 - 02.2007
- Marketing and IST-Management of Oncology drugs.
- Re-launch of and Marketing for MabCampath (CLL)
- IST-Management for PTKZK in solid tumors for ClinDev
- KOL Management Germany
Analyst, Consultant, Senior Consultant
Catenion Management Consulting
06.2001 - 01.2005
- Exclusively Pharma R&D Consulting.
- R&D Process Optimisation
- Clinical Development Strategy
- Brand Positioning
Education
Dr. (PhD) - Molecular Biology
Free University
01.2001
Bachelor - Business Administration
University Hagen
01.2000
Diploma - Chemistry
ETH Zürich & Harvard Univ.
01.1996
Skills
- Management consulting expertise
- Business operations management
- Pharmaceutical market access expertise
- Brand strategy development
- Claims data analysis
- Specialization in rare diseases
- Office
- Windows operating system proficiency
- Proficient in Mac OS
- Budgeting and forecasting
- Data analysis expertise
- Proficient in web technologies
Accomplishments
Built and sold an AI based medical tourism startup in China.
LANGUAGES
German (native)
English (fluent)
French (beginner)
Timeline
Head Drug Development, Value Strategy & Market Acc
Horváth & Partners
04.2024 - Current
Senior Director, Access Based Commercial Strategy
Simon-Kucher & Partners
03.2019 - 03.2024
Co-Founder and CEO
HTB HealthTechBerlin
01.2018 - 03.2022
General Manager, Head of Operations
HGC Healthcare Consulting
09.2015 - 12.2017
Business Unit Head, Oncology (interim)
Eisai Pharmaceuticals, Germany
01.2015 - 08.2015
SENIOR PRINCIPAL
IMS Consulting Group
12.2013 - 01.2015
Senior Director / PRINCIPAL
Campbell Alliance
09.2011 - 11.2013
Head BU Oncology, EMEA
IMS Health
03.2007 - 08.2011
Medical Liaison Manager, Senior Brand Manager
Schering (Pharmaceuticals), Germany
02.2005 - 02.2007
Analyst, Consultant, Senior Consultant
Catenion Management Consulting
06.2001 - 01.2005
Bachelor - Business Administration
University Hagen
Diploma - Chemistry
ETH Zürich & Harvard Univ.
Dr. (PhD) - Molecular Biology
Free University
CAREER HIGHLIGHTS
- Building and implementing a new integrated Data & Consulting Service Portfolio for IMS Health across EMEA, including hiring & training new Sales Forces in Turkey, Netherlands and UK.
- Restructuring of HGC and transforming it from a Data Analytics provider into an integrated Market Access / HEOR specialty Consultancy.
- Successful launches of two innovative pharma products in Diabetes & Thyroid Cancer as Manager in charge and a successful re-launch in CLL.
- Various publications, e.g. European Paper Study on HTA Harmonization, cell and gene therapy business models, orphan drug launches
References
Dr. Thomas Gottlieb, CBO Rotop Pharmaka (+49 163 7737 142)
Dr. Dirk Bernhardt, VP Market Access ITM Pharmasolutions (+49 172 85 11 017)
Jedd Comiskey, Head EUROPE Outlook Therapeutics (+41 78 252 1139)
SOCIAL MEDIA
- LinkedIn https://de.linkedin.com/in/dr-wolfram-lux-336a3526
- Xing https://www.xing.com/profile/Wolfram_Lux (outdated)
Similar Profiles
Melissa DiassoMelissa Diasso
Dental Assistant at Dental Partners of Towson & Dental Partners of Owings MillsDental Assistant at Dental Partners of Towson & Dental Partners of Owings Mills
OKUWA EBUNJESU SAMUELOKUWA EBUNJESU SAMUEL
PROJECT ENGINEER at Sanni, Ojo and Partners Consulting Limited, Ojo and Partners Consulting Limited, SOPPROJECT ENGINEER at Sanni, Ojo and Partners Consulting Limited, Ojo and Partners Consulting Limited, SOP
Sarthak ShahSarthak Shah
Tax Associate at Apple Growth Partners (Burton Partners)Tax Associate at Apple Growth Partners (Burton Partners)
Khouloud OuelhaziKhouloud Ouelhazi
Buchhalterin at LucaPacioli Accounting and Audit FirmBuchhalterin at LucaPacioli Accounting and Audit Firm
Kingsley Chigozie ANTHONYKingsley Chigozie ANTHONY
NA at NANA at NA